Printer Friendly

Shire brings legal suit against Corepharma.

Shire plc (Basingstoke, England) announced that its subsidiary Shire Laboratories Inc. has filed a lawsuit in the United States District Court for the District of New Jersey against Corepharma LLC ("Corepharma") for infringement of Shire Laboratories' United States Patents 5,326,570 ("'570 Patent ") and 5,912,013 ("'013 Patent ").

The lawsuit results from an Abbreviated New Drug Application ("ANDA") filed by Corepharma for generic versions of Shire's 100 mg, 200 mg, and 300 mg CARBATROL products, as to which Corepharma provided notice to Shire that it is seeking FDA approval to market its generic products prior to the expiration of the '570 and '013 Patents. Pursuant to Hatch-Waxman legislation, the lawsuit triggers a stay of FDA approval of up to 30 months from Corepharma's notice to allow the court to resolve the suit.

Shire's strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on central nervous system, gastrointestinal, general products and human genetic therapies. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

Shire plc

+44-1256-894-160

www.shire.com
COPYRIGHT 2006 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:May 1, 2006
Words:254
Previous Article:R&D budgets set to grow with China the biggest recipient.
Next Article:Amarin acquires Parkinson's disease drug candidate oral formulation of apomorphine to treat "off" episodes.
Topics:


Related Articles
Shire obtains positive outcome in Biochem patent litigation.
PLEA BARGAINS ACCEPTED IN CHILD'S DEATH KILLER RECEIVES LIFE SENTENCE.
FATHER, 25, CHARGED IN SON'S DEATH; EX-CONVICT BEAT 2-YEAR-OLD FOR STARING, AUTHORITIES SAY.
CHARGES REFILED AGAINST FATHER OF DEAD BOY.
COUPLE FACES SECOND SET OF CHARGES IN TODDLER'S DEATH; PROSECUTORS GATHER WITNESSES FOR NEW PRELIMINARY HEARING.
JUDGE DROPS CHARGES IN TOT'S DEATH.
NEWHALL COUPLE PLEADS NOT GUILTY IN SON'S DEATH.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters